JNCCN CME Accreditation
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation on the activity.
This educational activity was planned and produced in accordance with ACCME Essential Areas and Policies.
The NCCN adheres to the ACCME Standards for Commercial Support of Continuing Medical Education.
This activity is approved for 1.0 contact hours. NCCN is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission Accreditation of PA Nurses approval or endorsement of any product. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
Continuing Education Information
Target Audience This educational program is designed to meet the needs of oncologists, hematologists, advanced practice nurses, and other clinical professionals who treat and manage patients with cancer.
Educational Objectives
After completion of this CME/CE activity, participants should be able to:
• Review the current standard of care in patients with CML.
• Discuss the clinical data supporting the use of second generation TKIs for newly diagnosed patients with CML.
• Discuss the importance of monitoring response and mutational analysis.
• Describe the role of allogeneic stem cell transplant in the management of patients with CML.
• Summarize the NCCN Task Force recommendations for TKI therapy selection.
The opinions expressed in this publication are those of the participating faculty and not those of NCCN, Novartis Oncology, Otsuka America Pharmaceutical, Inc., or the manufacturers of any products mentioned herein.
This publication may include the discussion of products for indications not approved by the FDA.
Participants are encouraged to consult the package inserts for updated information and changes regarding indications, dosages, and contraindications. This recommendation is particularly important with new or infrequently used products.
Activity Instructions
Participants will read all portions of this monograph, including all tables, figures, and references. To receive your continuing education credit and certificate, visit http:// guest.cvent.com/d/xdqbsl to complete the post-test and evaluation. A minimum passing score of 70% is required on the post-test to be eligible for credits. If a minimum score is not achieved, you will be sent an e-mail with the opportunity to retake the test.
All post-test scores must be received by midnight on February 4, 2012, in order to be eligible for credit.
It should take approximately 1.0 hours (60 minutes) to complete the activity as designed. There is no registration fee for this activity. Certificates for passing scores will be e-mailed within 15 business days of submission of post-test and evaluation.
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Post-test
To Receive Credit
To receive credit, participants will read all portions of this monograph, including all tables, figures, and references. To receive your continuing education credit and certificate, visit http://guest.cvent.com/d/6dqbxf to complete the post-test and evaluation. All post-test scores must be received by midnight on February 4, 2012, in order to be eligible for credit.
It should take approximately 1.0 hours (60 minutes) to complete the activity as designed. There is no registration fee for this activity.
